{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T20:21:08Z","timestamp":1698956468056},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s11934-008-0080-6","type":"journal-article","created":{"date-parts":[[2008,11,26]],"date-time":"2008-11-26T15:49:31Z","timestamp":1227714571000},"source":"Crossref","is-referenced-by-count":5,"title":["The effects of reformulation: Improved therapeutic index"],"prefix":"10.1007","volume":"9","author":[{"given":"Scott","family":"MacDiarmid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Bobby W.","family":"Sandage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bimal K.","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,25]]},"reference":[{"key":"80_CR1","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P. Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology in lower urinary tract function: report from the Standardization Sub-Committee of the International Continence Society. Urology 2003, 61:37\u201349.","journal-title":"Urology"},{"key":"80_CR2","first-page":"56","volume":"44","author":"W.F. Stewart","year":"1999","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol 1999, 44:56\u201366.","journal-title":"World J Urol"},{"key":"80_CR3","first-page":"S580","volume":"6","author":"P. Abrams","year":"2000","unstructured":"Abrams P, Kelleher CJ, Kerr LA, Rogers RG: Overactive bladder significantly affects quality of life. Am J Manag Care 2000, 6:S580\u2013S590.","journal-title":"Am J Manag Care"},{"key":"80_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1046\/j.1474-8673.2002.00258.x","volume":"22","author":"R. Chess-Williams","year":"2002","unstructured":"Chess-Williams R: Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autocoid Pharmacol 2002, 22:133\u2013145.","journal-title":"Auton Autocoid Pharmacol"},{"key":"80_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/sj.bjp.0704781","volume":"136","author":"A. Fetscher","year":"2002","unstructured":"Fetscher A, Fleichman M, Schmidt M, et al.: M3 muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 2002, 136:641\u2013643.","journal-title":"Br J Pharmacol"},{"key":"80_CR6","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2165\/00003088-200342140-00004","volume":"42","author":"D.R.P. Guay","year":"2003","unstructured":"Guay DRP: Clinical pharmocokinetics of drugs used to treat urge incontinence. Clin Pharmocokinet 2003, 42:1243\u20131285.","journal-title":"Clin Pharmocokinet"},{"key":"80_CR7","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0022-5347(01)65148-6","volume":"157","author":"K. Waldeck","year":"1997","unstructured":"Waldeck K, Larrson B, Andersson K-E: Comparison of oxybutynin and its active metabolite N-desethyloxybutynin in the human detrusor and parotid gland. J Urol 1997, 157:1093\u20131097.","journal-title":"J Urol"},{"key":"80_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2165\/00002512-199506030-00007","volume":"6","author":"Y.E. Yarker","year":"1995","unstructured":"Yarker YE, Goa KI, Firton A: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995, 6:243\u2013262.","journal-title":"Drugs Aging"},{"issue":"Suppl1","key":"80_CR9","first-page":"S48","volume":"16","author":"J.W. Thuroff","year":"1995","unstructured":"Thuroff JW, Chartier-Kastler E, Corcus J, et al.: Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 1995, 16(Suppl 1):S48\u2013S61.","journal-title":"World J Urol"},{"key":"80_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","volume":"50Suppl6A","author":"R.A. Appell","year":"1997","unstructured":"Appell RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997, 50(Suppl 6A):90\u201396.","journal-title":"Urology"},{"key":"80_CR11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/009127009903900313","volume":"39","author":"S. Gupta","year":"1999","unstructured":"Gupta S, Sathyan G: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999, 39:22\u201329.","journal-title":"J Clin Pharmacol"},{"key":"80_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1046\/j.0306-5251.2001.01463.x","volume":"52","author":"G. Sathyan","year":"2001","unstructured":"Sathyan G, Chancellor MB, Gupta SK: Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride. Br J Clin Pharmacol 2001, 52:409\u2013417.","journal-title":"Br J Clin Pharmacol"},{"key":"80_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1177\/00912700122010014","volume":"41","author":"G. Sathyan","year":"2001","unstructured":"Sathyan G, Hu W, Gupta SK: Lack of effect of food on the pharmacokinetics of an extended release oxybutynin formulation. J Clin Pharmacol 2001, 41:187\u2013192.","journal-title":"J Clin Pharmacol"},{"key":"80_CR14","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","volume":"161","author":"R.U. Anderson","year":"1999","unstructured":"Anderson RU, Mobley D, Blank B, et al.: Once-daily controlled versus immediate-release oxybutynin chloride for urge incontinence. J Urol 1999 161:1809\u20131812.","journal-title":"J Urol"},{"key":"80_CR15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","volume":"78","author":"A.C. Diokno","year":"2003","unstructured":"Diokno AC, Appell RA, Sand P, et al.: Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003, 78:687\u2013695.","journal-title":"Mayo Clin Proc"},{"key":"80_CR16","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S0029-7844(99)00661-4","volume":"95","author":"E. Versi","year":"2000","unstructured":"Versi E, Appell R, Mobley D, et al.: Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. Obstet Gynecol 2000, 95:718\u2013721.","journal-title":"Obstet Gynecol"},{"key":"80_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1023\/A:1022259011052","volume":"20","author":"R.H. Zobrist","year":"2003","unstructured":"Zobrist RH, Quan D, Thomas HM, et al.: Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Rev 2003, 20:103\u2013109.","journal-title":"Pharm Rev"},{"key":"80_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.urology.2005.11.039","volume":"67","author":"V.W. Nitti","year":"2006","unstructured":"Nitti VW, Sanders S, Staskin DR, et al.: Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology 2006, 67:657\u2013664.","journal-title":"Urology"},{"key":"80_CR19","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00006842-199907000-00023","volume":"61","author":"J. Irvine","year":"1999","unstructured":"Irvine J, Baker B, Smith J, et al.: Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian amiodarone myocardial infarction arrhythmia trial. Psychoom Med 1999, 61:566\u2013575.","journal-title":"Psychoom Med"},{"key":"80_CR20","doi-asserted-by":"crossref","unstructured":"Haynes RB, McDonald H, Garg AX, Montague P: Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev 2002:CD000011.","DOI":"10.1002\/14651858.CD000011"},{"key":"80_CR21","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0149-2918(03)80222-9","volume":"25","author":"A. Richter","year":"2003","unstructured":"Richter A, Anton SE, Koch P, Dennett SL: The impact of reducing dose frequency on health outcomes. Clin Ther 2003, 25:2307\u20132335.","journal-title":"Clin Ther"},{"key":"80_CR22","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0022-5347(05)64684-8","volume":"168","author":"R.R. Dmochowski","year":"2002","unstructured":"Dmochowski RR, Davilla GW, Zinner NR, et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002, 168:580\u2013586.","journal-title":"J Urol"},{"key":"80_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","volume":"62","author":"R.R. Dmochowski","year":"2003","unstructured":"Dmochowski RR, Sand PK, Zinner NR, et al.: Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003, 62:237\u2013242.","journal-title":"Urology"},{"key":"80_CR24","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1600-0773.1999.tb02026.x","volume":"85","author":"S. Beckman-Knopp","year":"1999","unstructured":"Beckman-Knopp S, Rietbrock S, Weyhenmeyer R, et al.: Inhibitory effects of trospium chloride on cytochrome P450 enzyme in human liver microsomes. Pharmacol Toxicol 1999, 85:299\u2013304.","journal-title":"Pharmacol Toxicol"},{"key":"80_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003088-200544070-00003","volume":"44","author":"O. Doroshyenko","year":"2005","unstructured":"Doroshyenko O, Jetter A, Odenthal KP, Fuhr U: Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005, 44:701\u2013720.","journal-title":"Clin Pharmacokinet"},{"key":"80_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/j.1464-410X.2005.05913.x","volume":"97","author":"Y.T. Kim","year":"2006","unstructured":"Kim YT, Yoshimura N, Masuda H, et al.: Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 2006, 97:400\u2013403.","journal-title":"BJU Int"},{"key":"80_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.urology.2005.08.017","volume":"67","author":"D. Rudy","year":"2006","unstructured":"Rudy D, Cline K, Harris R, et al.: Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006, 67:275\u2013280.","journal-title":"Urology"},{"key":"80_CR28","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1097\/01.ju.0000127742.73136.0c","volume":"171","author":"N. Zinner","year":"2004","unstructured":"Zinner N, Gittleman M, Harris R, et al.: Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004, 171:2311\u20132315.","journal-title":"J Urol"},{"key":"80_CR29","unstructured":"Data on file at Indevus Pharmaceuticals."},{"key":"80_CR30","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.juro.2007.05.058","volume":"178","author":"D. Staskin","year":"2007","unstructured":"Staskin D, Sand P, Zinner N, et al.: Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007, 178:978\u2013984.","journal-title":"J Urol"},{"key":"80_CR31","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","volume":"60","author":"L. Nilvebrant","year":"1997","unstructured":"Nilvebrant L, Hallen B, Larsson G: Tolterodine\u2014a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci 1997, 60:1129\u20131136.","journal-title":"Life Sci"},{"key":"80_CR32","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/S0024-3205(01)01051-7","volume":"68","author":"L. Nilvebrant","year":"2001","unstructured":"Nilvebrant L: Clinical experiences with tolterodine. Life Sci 2001, 68:2549\u20132556.","journal-title":"Life Sci"},{"key":"80_CR33","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S0090-4295(98)00629-3","volume":"53","author":"G. Larsson","year":"1999","unstructured":"Larsson G, Hallen B, Nilvebrant L: Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999, 53:990\u2013998.","journal-title":"Urology"},{"key":"80_CR34","unstructured":"Detrol. Prescribing information. Available at http:\/\/media.pfizer.com\/files\/products\/uspi_detrol_la.pdf . Accessed July 2, 2008."},{"key":"80_CR35","first-page":"287","volume":"35","author":"N. Brynn","year":"1997","unstructured":"Brynn N, Stahl M, Hallen B, et al.: Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997, 35:287\u2013295.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"80_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2165\/00003088-200140030-00006","volume":"40","author":"B. Olsson","year":"2001","unstructured":"Olsson B, Szamosi J: Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001, 40:227\u2013235.","journal-title":"Clin Pharmacokinet"},{"key":"80_CR37","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","volume":"57","author":"P. Kerrebroeck Van","year":"2001","unstructured":"Van Kerrebroeck P, Kreder K, Jonas U, et al.: Tolterodine once daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001, 57:414\u2013421.","journal-title":"Urology"},{"key":"80_CR38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.urology.2005.10.061","volume":"67","author":"R. Rackley","year":"2006","unstructured":"Rackley R, Weiss JP, Rovner ES, et al.: Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006, 67:731\u2013736.","journal-title":"Urology"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-008-0080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11934-008-0080-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-008-0080-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-008-0080-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,21]],"date-time":"2023-05-21T14:09:51Z","timestamp":1684678191000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11934-008-0080-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["80"],"URL":"https:\/\/doi.org\/10.1007\/s11934-008-0080-6","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]},"article-number":"465"}}